CoLucid Pharmaceuticals Priced, Nasdaq: CLCD

Late-stage biotech developing therapies for acute migraines.

Industry: Health Care

Latest Trade: $46.53 0.00 (0.0%)

First Day Return: -20.0%

Return from IPO: +365.3%

Industry: Health Care

We are a Phase 3 clinical-stage biopharmaceutical company that is developing an innovative and proprietary small molecule for the acute treatment of migraine headaches. Our product candidates utilize the first new mechanism of action in the last twenty years, which we believe could address the unmet needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those who are dissatisfied with existing therapies. Lasmiditan, our lead product candidate, is an oral tablet for the acute treatment of migraine headaches in adults that does not have the clinical limitations associated with the most commonly used therapies. In our Phase 2b clinical trial of lasmiditan, we met our primary endpoint of headache relief with statistical significance as well as our secondary endpoint of freedom from the associated symptoms of nausea, sensitivity to sound and sensitivity to light. Headache relief is defined as reducing a moderate or severe headache at baseline to mild or none two hours after dosing. In our completed clinical trials, lasmiditan was well tolerated and had a favorable patient global impression of change, an indicator of patient satisfaction.
more less
IPO News for CoLucid Pharmaceuticals
more
IPO Data
IPO File Date 03/30/2015
Offer Price $10.00
Price Range $10.00 - $10.00
Offer Shares (mm) 5.5
Deal Size ($mm) $55
IPO Data
IPO Date 05/05/2015
Offer Price $10.00
Price Range $10.00 - $10.00
Offer Shares (mm) 5.5
Deal Size ($mm) $55
Underwriters
more
Company Data
Headquarters Burlington, MA
Founded 2005
Employees 5
Website www.colucid.com